

The CRISPR Analytics Platform

Providing the data needed for precise and safe gene-editing



Having trouble achieving consistent high-quality CRISPR edits?


Here at CRISPR QC, we're familiar with the headache that comes with troubleshooting gene editing outcomes.

With so many potential factors affecting editing success and no good means to assess them, pinpointing the source of variation in your edits can seem like a daunting task.

Current techniques such as cell assays and NGS are of little help, as they are limited to assessing the end result of an edit.

Gain insight to key factors driving editing success

Powered by our patent- protected CRISPR-CHIP[™] and robotic reader, our CRISPR Analytics Platform simulates gene editing in real-time, providing unique biochemical insights to optimize editing outcomes.



The CRISPR Analytics Platform

Process



Contact our

science team

Send us your

reagents



CRISPR Analytics Platform goes to work



Data and report

presented to you

containing findings is

-->)



Simplified, streamlined editing workflow

How our Data Benefits your programs



Reach your Milestones

Quit missing milestones due to outcomes that did not line up with what models and sequencing foretold



Shorten R&D Cycles

Better data means your R&D team has the tools it needs to do more in less time



Quality Control


Ensure that your reagents are delivering consistent performance

Lets Work Together

Please get in touch to discuss how our data and collaborative approach can optimize your CRISPR editing programs (864) 494-7223

zack@crisprqc.com

8949 Kenamar Dr. Suite 101 San Diego, CA 92121



Case Studies

Saving Customer Weeks with Better gRNA selection


Problem: Established In-silico gRNA selection models failed to accurately predict outcomes - costing customer weeks of lost work.

Customer Solution: CRISPR QC identified the highest- performing gRNAs using our unique activity data, enabling them to achieve their desired gene edit.

NIST Collaboration: Establishing CRISPR Measurement Standards

Problem: Lack of standards and consistent methods plague the CRISPR therapeutic industry, FDA & NIST working to build measurements and standards to lift industry and protect patients

Study: CRISPR QC and NIST collecting data that is demonstrating CRISPR QC measurements can predict cellediting outcomes. Study in final stages.



CRISPR



repeated experiments due to suboptimal gRNA

s

wasted time, money, reagents

